Literature DB >> 22544819

Wingspan experience in the treatment of symptomatic intracranial atherosclerotic disease after antithrombotic failure.

Edgar A Samaniego1, Francesca Tari-Capone, Italo Linfante, Christine F Silva, Gabriela Spilberg, Matthew Gounis, Ajay K Wakhloo, Guilherme Dabus.   

Abstract

BACKGROUND AND
PURPOSE: Intracranial stenting with the Wingspan system has been used as a revascularization strategy in symptomatic patients with intracranial atherosclerotic disease (ICAD). The latest results of the Stenting versus Aggressive Medical Therapy for Intracranial Artery Stenosis (SAMMPRIS) trial challenge this approach. Our experience in the treatment of symptomatic ICAD with the Wingspan system is reported.
MATERIALS AND METHODS: Patients who underwent stenting for symptomatic ICAD were included in the analysis. Demographic data, periprocedural complications, long term radiological and clinical outcomes are reported.
RESULTS: 46 lesions were treated in 45 patients. 13 patients (29%) presented with a transient ischemic attack and 32 (71%) with a stroke. 43 patients (95.5%) failed antithrombotic therapy at presentation. One (2%) symptomatic periprocedural (24 h) complication occurred. The 30 day incidence of stroke and vascular death was 6.6%--a fatal hemorrhagic stroke and two non-fatal hemorrhagic strokes. In-stent stenosis (≥50%) was seen in nine (42.8%) lesions, two were symptomatic.
CONCLUSIONS: This cohort of patients with symptomatic ICAD who failed antithrombotic medications benefited from angioplasty and stenting with the Wingspan system.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544819     DOI: 10.1136/neurintsurg-2012-010321

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  8 in total

1.  Endovascular Recanalization in Early Recurrent Ischemic Stroke: A Treatment Challenge.

Authors:  Huong Bich Thi Nguyen; Thang Huy Nguyen
Journal:  Case Rep Neurol       Date:  2020-12-14

2.  The effectiveness of enterprise stent use on the treatment of intracranial atherosclerosis disease.

Authors:  Oguz Ari; Omer F Nas; Mehmet F Inecikli; Bahattin Hakyemez
Journal:  Neuroradiol J       Date:  2022-04-07

3.  Incidence and Risk Factors of In-Stent Restenosis for Symptomatic Intracranial Atherosclerotic Stenosis: A Systematic Review and Meta-Analysis.

Authors:  G Peng; Y Zhang; Z Miao
Journal:  AJNR Am J Neuroradiol       Date:  2020-07-30       Impact factor: 3.825

4.  Undersized angioplasty and stenting of symptomatic intracranial tight stenosis with Enterprise: Evaluation of clinical and vascular outcome.

Authors:  Kun-Yu Lee; David Yen-Ting Chen; Hui-Ling Hsu; Chi-Jen Chen; Ying-Chi Tseng
Journal:  Interv Neuroradiol       Date:  2015-11-04       Impact factor: 1.610

5.  Quantitative analysis of high-resolution, contrast-enhanced, cone-beam CT for the detection of intracranial in-stent hyperplasia.

Authors:  Thomas F Flood; Imramsjah M J van der Bom; Lara Strittmatter; Ajit S Puri; Gregory M Hendricks; Ajay K Wakhloo; Matthew J Gounis
Journal:  J Neurointerv Surg       Date:  2014-01-30       Impact factor: 5.836

6.  Enterprise stent for the treatment of symptomatic intracranial atherosclerotic stenosis: an initial experience of 44 patients.

Authors:  Zhengzhe Feng; Guoli Duan; Ping Zhang; Lei Chen; Yi Xu; Bo Hong; Wenyuan Zhao; Jianmin Liu; Qinghai Huang
Journal:  BMC Neurol       Date:  2015-10-08       Impact factor: 2.474

7.  Tissue Kallikrein Prevents Restenosis After Stenting of Severe Atherosclerotic Stenosis of the Middle Cerebral Artery: A Randomized Controlled Trial.

Authors:  Ruifeng Shi; Renliang Zhang; Fang Yang; Min Lin; Min Li; Ling Liu; Qin Yin; Hang Lin; Yunyun Xiong; Wenhua Liu; Xiaobing Fan; Qiliang Dai; Lizhi Zhou; Wenya Lan; Qinqin Cao; Xin Chen; Gelin Xu; Xinfeng Liu
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

8.  Endovascular Treatment of Intracranial Atherosclerotic Stenosis: Current Debates and Future Prospects.

Authors:  Jichang Luo; Tao Wang; Peng Gao; Timo Krings; Liqun Jiao
Journal:  Front Neurol       Date:  2018-08-21       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.